susceptibility to amphotericin B and all azoles at pH 4. In contrast, fluconazole sensitive C. 48 albicans isolates remained susceptible at low pH to azoles in keeping with clinical observations. 49
In selecting agents for treatment of recurrent C. glabrata vaginitis, clinicians should recognize 50 the limitations of in vitro susceptibility utilizing pH 7.0. 51 3 Vulvovaginal candidiasis (VVC) accounts for up to one third of all vaginitis cases presenting to 53 gynecologists. [1] [2] [3] VVC is most commonly caused by Candida albicans, but can also be caused by 54 non-albicans Candida species, with Candida glabrata being the most common. 24, 26 Symptomatic 55 C. glabrata vaginitis poses a significant problem for clinicians because effective treatment and 56 eradication of C. glabrata from the vagina has proven difficult. 23, 25, 26 The organism has variable 57 intrinsic resistance to azole drugs. 23, 25, 26 C. glabrata vaginitis has been moderately successfully 58 treated with boric acid, yet this is not curative in one third of patients. 8, 23, 25, 26 Other therapies 59
have been advocated such as topical flucytosine, oral itraconazole, and nystatin suppositories.
8,18

60
Amphotericin B suppositories in patients with non-albicans Candida resistant to azoles were 61 studied by Phillips, and found to be promising, however symptomatic C. glabrata vaginitis is 62 often unresponsive to these regimens. 11, 18 VVC is also occasionally caused by fluconazole 63 resistant C. albicans, posing a similar treatment dilemma in that susceptibility of these organisms 64 to other azole and non-azole drugs is not clinically predictive. 26 
65
Drug treatment of vaginal infections may be unique in that the normal pH of the vagina is 66 4 to 4.5, which remains unchanged during VVC. 13 Previous studies have found that the test 67 medium pH in in vitro susceptibility testing can alter the azole minimum inhibitory concentration 68 (MIC) for Candida species, and that an acidic pH tends to increase the MICs of fluconazole for 69 selected Candida species. 16 However, it was concluded that more acidic conditions did not 70 change the designation of the isolates from susceptible to resistant neither were clinical 71 implications evident. The purpose of this study was to determine whether a change in test media 72 pH had an effect on in vitro susceptibility of C. glabrata and both fluconazole-susceptible and 73 reduced-susceptibility C. albicans to 7 azole and 4 non-azole antifungal agents, in order to 74 explain frequent in vivo failure of these agents in women with vaginitis caused by C. glabrata. 
Materials and Methods: 76
Vaginal isolates of C. glabrata and C. albicans were chosen from the Wayne State 77
Vaginitis Clinic microbiology laboratory organism bank. The definition of fluconazole 78 susceptible C. albicans was a MIC ≤ 2 µg/mL, and MIC > 4 µg/mL for reduced susceptibility 79
isolates. 4 Vaginal isolates were randomly chosen from the years 2000-2010, and plated on 80
CHROMagar to verify purity of culture. These plates were incubated for 48 hours at 37ºC in 81 ambient air. Susceptibility testing was then performed using a broth microdilution method, 82 according to CLSI document M27-A3 (2008) guidelines utilizing pH 7.
4 Antifungals and 83 including ranges of antifungal agents tested for each pH value for both C. glabrata and C. 100
albicans. 101
C. glabrata 102
At pH 7, all C. glabrata isolates were susceptible to flucytosine, amphotericin B, 103 caspofungin and ciclopiroxolamine. In contrast, a range of in vitro activity was present for the 104 various azole agents. The MIC 90 for fluconazole was 32 ug/mL (range 2 to >64 ug/ml) with 105 considerably lower MIC's for all other azoles tested. Notably low MICs were documented for 106 posaconazole and voriconazole at 0.5ug/mL. Itraconazole and ketoconazole were highly active at 107 pH 7 and the topical agents clotrimazole and miconazole were similarly active. 108
With progressive reduction in pH, MIC 90 values for 5-FC and caspofungin were 109 unchanged, however an increase in MIC was evident for amphotericin B and to a less extent 110 ciclopiroxolamine. A dramatic increase in MIC 90 was evident for all azoles tested to drug levels 111 achievable in the vagina with systemic azole use, although pharmacologic data are not available. 112
The trends observed for MIC 90 was also reflected in MIC 50 values. 113
C. albicans 114
At pH 7, fluconazole-susceptible strains of C. albicans were predictably susceptible to all 115 antifungal agents tested. With decrease in pH, a significant increase in MIC was evident only 116 with amphotericin B and ciclopiroxolamine. Azole activity at the lower pH was maintained in 117 the fluconazole susceptible isolates. 118
At pH 7, 10 vaginal isolates of fluconazole-reduced susceptibility C. albicans were 119 evaluated. MIC range for fluconazole activity was 4 to >64 ug/mL, with MIC 90 being 4ug/mL. 
Discussion: 125
The results of this study reveal that different classes of antifungals and the two species of 126
Candida studied in vitro behaved differently with decrease in pH. The results confirm the 127 susceptibility of fluconazole sensitive C. albicans isolates to all azoles and C. glabrata's variable 128 resistance to fluconazole, and may also offer insight as to why some antifungal medications may 129 not be as effective in vivo with a more acidic physiologic vaginal pH. Previous studies similarly 130 found that the medium pH can alter azole MICs for Candida species, and specifically an acidic 131 pH was reported to increase the MICs of fluconazole for selected Candida species. 16 The clinical 132 implications of this observation were not, however, recognized. 133
C. glabrata vaginal infection is by no means infrequent, but case numbers are insufficient 134
to perform a randomized controlled trial in order to establish optimal treatment. 23 
11,18 Topical amphotericin B has also been used in combination with other 153 antifungals, such as flucytosine. If flucytosine is as effective as previously described and stable 154 at a low pH, perhaps it is contributing much more than amphotericin B to successful treatment. 25 
155
In the present study that for both Candida species, amphotericin B activity was profoundly 156 affected by pH with at least a 16-fold increase in MIC 90 with decrease in pH. 157
Ciclopiroxolamine is an agent applied topically and well known for its potency against 158 dermatophytes, and has been suggested as an antifungal for resistant VVC. It is a synthetic 159 topical agent, widely used to treat onychomycosis, tinea pedis, pityriasis versicolor and 160 seborrheic dermatitis. Its use in treating vaginal candidiasis has also been studied, with limited 161 success, 9,17, 21 and has shown clinical promise against azole-resistant Candida species, including 162 C. glabrata. It has demonstated good topical and systemic tolerance in rats and rabbits when 163 vaginal tissue was examined, 5, 15 and has been studied in setting with lower pH. 9,10 However, in 164 this study, a 4-fold rise in MIC 90 from 0.5 to 2 ug/mL with a decrease in pH was seen . One 165 factor that limits the clinical application of this data is that the break point of ciclopiroxolamine 166 is unknown and the clinical relevance of increased MIC's is questionable. 
